Vanguard Global Advisers
PVLA

Vanguard Global Advisers’s Palvella Therapeutics PVLA Stock Holding History

Vanguard Global Advisers’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$949K Hold
6,209
– – ﹤0.01% 1776
2026
Q1 		$774K Buy
+6,209
New +$648K ﹤0.01% 1792

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Global Advisers's PVLA Position: Q2 2026 in Review

Vanguard Global Advisers held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 6,209 shares worth $949K. The position accounts for ﹤0.01% of the portfolio, ranked #1776.

Vanguard Global Advisers first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Vanguard Global Advisers held 6,209 shares of Palvella Therapeutics worth $949K as of Q2 2026.
  • Vanguard Global Advisers left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1776 holding.
  • Vanguard Global Advisers first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.